170853-04-0

Basic information

• Product Name: TERT-BUTYL 3-FORMYLBENZYLCARBAMATE
• Synonyms: 3-(AMINOMETHYL)BENZALDEHYDE, N-BOC PROTECTED;TERT-BUTYL 3-FORMYLBENZYLCARBAMATE;tert-butyl n-(3-formylbenzyl)carbamate;3-(Aminomethyl)benzaldehyde, N-BOC protected 90%;tert-butyl N-[(3-forMylphenyl)Methyl]carbaMate;tert-Butyl (3-formylbenzyl)carbamate, 3-Formylbenzylamine, N-BOC protected;3-(Aminomethyl)benzaldehyde,N-BOCprotected90%;N-Boc-3-formylbenzylamine
• CAS NO: 170853-04-0
• Molecular Formula: C₁₃H₁₇NO₃
• Molecular Weight: 235.28
• Mol File: 170853-04-0.mol
• Article Data: 7

Chemical Properties

• Melting Point: 59 °C
• Boiling Point: 382.9 °C at 760 mmHg
• Flash Point: 185.3 °C
• Appearance: /
• Density: 1.108g/cm³
• Vapor Pressure: 4.58E-06mmHg at 25°C
• Refractive Index: 1.538
• PKA: 12.00±0.46(Predicted)
• CAS DataBase Reference: TERT-BUTYL 3-FORMYLBENZYLCARBAMATE(CAS DataBase Reference)
• NIST Chemistry Reference: TERT-BUTYL 3-FORMYLBENZYLCARBAMATE(170853-04-0)
• EPA Substance Registry System: TERT-BUTYL 3-FORMYLBENZYLCARBAMATE(170853-04-0)

Safety Data

• Hazard Codes: Xn
• Statements: 22-51
• Hazardous Substances Data: 170853-04-0(Hazardous Substances Data)

Usage

General Description

Tert-butyl 3-formylbenzylcarbamate is a chemical compound that consists of a tert-butyl group, a 3-formylbenzyl group, and a carbamate group. It is commonly used as a reagent in organic synthesis, especially in the modification of biomolecules and pharmaceuticals. TERT-BUTYL 3-FORMYLBENZYLCARBAMATE has been studied for its potential use in the development of new drugs and materials, and it is known for its ability to selectively modify specific functional groups in complex molecules. Tert-butyl 3-formylbenzylcarbamate has garnered interest in the research community for its unique reactivity and its potential applications in various fields.

InChI:InChI=1/C13H17NO3/c1-13(2,3)17-12(16)14-8-10-5-4-6-11(7-10)9-15/h4-7,9H,8H2,1-3H3,(H,14,16)

Upstream product

• 24964-64-5 3-Cyanobenzaldehyde 
• 4394-85-8 4-morpholinecarboxaldehyde 
• 171663-13-1 t-butyl N-(3-bromobenzyl)carbamate 
• 781632-38-0 3-(1, 3-Dioxo-1,3-dihydro-isoindol-2-ylmethyl)-benzoic acid methyl ester 
• 226070-69-5 1,1-dimethylethyl {[3-(hydroxymethyl)phenyl]methyl}carbamate 
• 117445-22-4 3-(tert-butoxycarbonylamino-methyl)benzoic acid 
• 1129-28-8 3-methoxycarbonylbenzyl bromide 
• 99-04-7 m-Toluic acid 
• 6515-58-8 3-bromomethylbenzoic acid 
• 180863-55-2 methyl 3-(((tert-butoxycarbonyl)amino)methyl)benzoate 
• 24424-99-5 di-tert-butyl dicarbonate 
• 39959-54-1 3-bromobenzylamine hydrochloride 
• 68-12-2 N,N-dimethyl-formamide 
• 153329-04-5 3-(1,3-dioxolan-2-yl)-benzonitrile 

Downstream Products

• 478929-86-1 {3-[3-(4(S)-benzyl-2-oxooxazolidin-3-yl)-1(R)-hydroxy-2(S)-isopropoxy-3-oxopropyl]benzyl}carbamic acid t-butyl ester 
• 171662-97-8 3-[3-(tert-butoxycarbonylamino-methyl)-phenyl]-acrylic acid methyl ester 
• 1035095-37-4 tert-butyl N-(3-((3-(1H-indazol-5-ylamino)piperidin-1-yl)methyl)phenyl)methyl carbamate 
• 942948-10-9 (3-{6-bromo-7-[4-(thiazol-2-ylcarbamoylmethyl)-piperazin-1-yl]-3H-imidazo[4,5-b]pyridin-2-yl}-benzyl)-carbamic acid tert-butyl ester 

Relevant articles and documents

Discovery of Tetrahydroisoquinoline-Containing CXCR4 Antagonists with Improved in Vitro ADMET Properties

CXCR4 is a seven-transmembrane receptor expressed by hematopoietic stem cells and progeny, as well as by ≥48 different cancers types. CXCL12, the only chemokine ligand of CXCR4, is secreted within the tumor microenvironment, providing sanctuary for CXCR4+ tumor cells from immune surveillance and chemotherapeutic elimination by (1) stimulating prosurvival signaling and (2) recruiting CXCR4+ immunosuppressive leukocytes. Additionally, distant CXCL12-rich niches attract and support CXCR4+ metastatic growths. Accordingly, CXCR4 antagonists can potentially obstruct CXCR4-mediated prosurvival signaling, recondition the CXCR4+ leukocyte infiltrate from immunosuppressive to immunoreactive, and inhibit CXCR4+ cancer cell metastasis. Current small molecule CXCR4 antagonists suffer from poor oral bioavailability and off-target liabilities. Herein, we report a series of novel tetrahydroisoquinoline-containing CXCR4 antagonists designed to improve intestinal absorption and off-target profiles. Structure-activity relationships regarding CXCR4 potency, intestinal permeability, metabolic stability, and cytochrome P450 inhibition are presented.

HISTONE DEACETYLASE INHIBITORS

The disclosure provides compounds of formula I and methods for preparation thereof. The compounds act as inhibitor of histone deacetylase.

Synthesis of photoswitchable hemithioindigo-based ω-amino acids and application in Boc-based peptide assembly

Efficient procedures for the preparation of the N-Boc-protected aldehydes 5a and 5b are described which are valuable precursors for the synthesis of hemithioindigo-based ω-amino acids and peptides. Georg Thieme Verlag Stuttgart.